Clinical Trial Update: A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center

View source ↗

Summary

A retrospective cohort study evaluates a single cycle of intravenous immunoglobulin as an adjuvant to rituximab in patients with pemphigus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)
• Rituxan (rituximab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Pemphigus Disease, Rituximab (RTx) | Status: ACTIVE_NOT_RECRUITING